Targeting the cholesterol-ROR alpha/gamma axis inhibits colorectal cancer progression through degrading c-myc

Ying-Nan Wang,Dan-Yun Ruan,Zi-Xian Wang,Kai Yu,Dai-Lin Rong,Ze-Xian Liu,Feng Wang,Jia-Jia Hu,Ying Jin,Qi-Nian Wu,Heng-Ying Pu,Min Wang,Rui-Hua Xu,Zhao-Lei Zeng

DOI: https://doi.org/10.1038/s41388-022-02515-3

IF: 8.756

2022-01-01

Oncogene

Abstract:Dysregulated cholesterol metabolism is a hallmark of colorectal cancer (CRC). However, the usage of cholesterol-lowering agents seemed to have no benefit in CRC patients. In this study, we focused on the cholesterol-nuclear receptors (NRs) axis as a strategy. Cholesterol and its derivatives work as ligands for different nuclear receptors, thus promoting cancer progression. The key NR downstream of cholesterol in CRC is unknown. Here, we treated CRC cells with a cholesterol-lowering agent and lipoprotein-depleted conditioned medium, and then detected the change of the putative NRs. The results revealed that ROR alpha/gamma (Retinoic acid receptor-related Orphan Receptor alpha/gamma) levels exhibited the most obvious increases in CRC cells subjected them to cholesterol deprivation. ROR alpha/gamma agonists significantly inhibited CRC cells proliferation and migration in vitro and in vivo. Also, ROR alpha/gamma overexpression repressed CRC cells proliferation and migration in vitro and in vivo and ROR alpha/gamma knockdown promoted it. Mechanistically, ROR alpha/gamma agonists promoted c-myc degradation by activating the transcription of the ubiquitinase NEDD4. Intriguingly, the combination of ROR alpha/gamma agonists and atorvastatin had a synergistic effect on inhibiting CRC cells. These findings demonstrate that the cholesterol- ROR alpha/gamma axis is important for maintaining c-myc protein levels. Combination therapy with atorvastatin and ROR alpha/gamma agonist is a promising therapeutic strategy for CRC.